Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone
Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.
Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.
Discover how Nicox SA’s NCX 470 Phase 3 data could reshape glaucoma treatment and regulatory strategy. Read the full analysis.
Kirin and Immunosens are developing a urinary IgA self-testing service to visualize immune status. Find out what this changes for consumer immune monitoring.
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
SCIEX integrates Echo MS+ with ZenoTOF 8600 to reshape high-throughput mass spectrometry workflows. Find out why this matters for discovery labs.
Evecxia’s Phase 1b study uses direct brain biomarkers to validate serotonin synthesis amplification. Find out why this matters for antidepressant development.
Fresenius Kabi and Phlow Corp. aim to onshore epinephrine production in the U.S. Find out whether this model can truly fix essential drug shortages.